Deliver meaningful impact faster with Steinschulte Pharma

 

Transformation is an ongoing process — formerly clearly defined initiatives evolve to an ongoing, purpose-driven permanent improvement. Business changes accelerate, leadership needs increased empathy, transparency and empowerment for all employees.

Steinschulte Pharma is a partner for the new rules of modern business.

We change or buy your business to get more sustainable, faster, more agile more profitable.

We WORK, RETHINK, CREATE and GROW together with you.

Our Vision

About Steinschulte Pharma

 

Pharmacist with PhD in Immunology

Deep marketing and sales experience of over 18 years from sales to CEO

General Management/ CEO positions/ supervisory board experience

Marketing as sales experience in many different roles

Pharma production

Supply change management

Governance

HR lead

QPPV

Quality lead

Outsourcing and insourcing projects

M&A

Restructuring

Consulting

Production site optimization

More than 5 years of commercial and launch experience in hemophilia with the number one plasma and recombinant brands  and launch of the first half life extended Fc Fusion proteins including hemophilia A and B (including AMNOG process), responsible for turnover of more than 200 million €.

Full Range of CNS Products (Schizophrenia, ADHS, Antidepressants, Antiepileptics, Treatment of Parkinson`s disease and responsible for turnover of more than 100 Million €.

Full Range of Rare Disease Products in the indications

Morbus Wilson,

cystinuria,

rare tumors,

mycosis fungoides,

NAGS deficiency and organic aciduria,

hypermethionemia,

cystinosis,

treatment of attacks of hepatic porphyria,

for closing patent ductus arteriosus

and treatment or prevention of vitamin E deficiency.

Experience in Botulinum Toxin market, being responsible a broad area of European countries.

Good knowledge in

antibiotics,  

anticoagulants

antihypertensives and 

antiarrhythmics 

Relaunch of cystinuria product with broad knowledge in that area

Rare disease child dosage antiepileptic product including AMNOG process

European launch of

ANCA vasculitis complement product, first innovation in decades (being involved in AMNOG)